Berlin N I
Sylvester Comprehensive Cancer Center, University of Miami, Florida, USA.
Eur J Haematol. 2000 Jul;65(1):1-7. doi: 10.1034/j.1600-0609.2000.9r119.x.
The use of radioactive phosphorus (32P) to treat the myeloproliferative disorders (chronic leukemia, polycythemia vera and essential thrombocythemia) began in 1939 when John H. Lawrence treated the first patient on the basis of work done in the laboratory animals that found localization of the radioisotope in the spleen, liver, bone and in leukemic cells sufficient to indicate a therapeutic potential. After World War II when 32P became widely available, it was used extensively to treat the chronic leukemias and polycythemia vera. Its use in the treatment of essential thrombocythemia began later in 1950. Today it is not widely used in the treatment of the chronic leukemia, if at all, its use in polycythemia vera appears to have decreased substantially and replaced by hydroxyurea, and its use in the management of essential thrombocythemia is not widespread. In each instance it has been replaced by a drug developed for use in cancer chemotherapy, and in some instances by interferon. It probably has wider use in polycythemia vera in the rest of Western Europe than in the UK, and there are cogent reasons to suggest that it may be the best tool for the treatment of polycythemia vera. Thus have we discarded a treatment modality that in polycythemia vera may be the best?
放射性磷（32P）用于治疗骨髓增殖性疾病（慢性白血病、真性红细胞增多症和原发性血小板增多症）始于1939年，当时约翰·H·劳伦斯根据在实验动物身上所做的工作治疗了首例患者，该工作发现放射性同位素在脾脏、肝脏、骨骼和白血病细胞中的定位足以显示其治疗潜力。第二次世界大战后，32P广泛可得，它被广泛用于治疗慢性白血病和真性红细胞增多症。它在原发性血小板增多症治疗中的应用始于1950年后期。如今，它在慢性白血病治疗中即便使用也并不广泛，在真性红细胞增多症中的应用似乎已大幅减少，被羟基脲所取代，并且它在原发性血小板增多症管理中的应用并不普遍。在每种情况下，它都已被开发用于癌症化疗的药物所取代，在某些情况下被干扰素所取代。在西欧其他地区，它在真性红细胞增多症中的应用可能比在英国更广泛，并且有充分理由表明它可能是治疗真性红细胞增多症的最佳工具。那么，我们就这样舍弃了一种在真性红细胞增多症中可能是最佳的治疗方式吗？
